Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution

Blog Article

Objective The outcomes of patients with acute myeloid leukemia (AML) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are poor.However, the risk factors for relapse in this context remain unclear.Methods We retrospectively assessed 84 consecutive adult AML patients who underwent allo-HSCT and achieved complete remission (CR).These patients were dichotomized into non-relapse (n = 58) and relapse (n = Bike Parts - Liners 26) groups, and the cumulative relapse rates and associated risk factors were examined.We also examined the treatments for and outcomes of patients with AML relapse after allo-HSCT.

Results Non-CR status before allo-HSCT and high-risk cytogenetics were significant risk factors for AML relapse in univariate analysis, and non-CR status was also identified as a risk factor in multivariate analysis.The cumulative AML relapse rates after allo-HSCT were significantly higher in patients with non-CR (70.0%) compared with patients with NUTRI C COMPLEX CR (25.6%).Only 2 of the 26 relapsed patients remained alive on the study-censored day.

Conclusions Non-CR status before allo-HSCT was a significant risk factor for AML relapse after allo-HSCT.Patients with AML relapse after allo-HSCT had poor outcomes due to a lack of response to salvage remission-induction chemotherapy or treatment-related adverse events.